Compounds > goralatide
Page last updated: 2024-08-24

goralatide and Body Weight

goralatide has been researched along with Body Weight in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Carretero, OA; Dai, X; González, GE; Leung, P; Liao, TD; Liu, Y; Nakagawa, P; Rhaleb, NE; Yang, XP1
André, S; Carretero, OA; D'Ambrosio, M; Gabius, HJ; Liao, TD; Liu, YH; Peng, H; Rhaleb, NE; Sharma, U1
Huang, B; Liang, Y; Tan, H; Wang, H; Wang, S; Yang, N; Yu, X; Zhang, L; Zhao, J1
Brigstock, DR; Carretero, OA; Oja-Tebbe, N; Peng, H; Rhaleb, NE1
Bogden, AE; Carde, P; de Paillette, ED; Frindel, E; Moreau, JP; Tubiana, M1

Other Studies

5 other study(ies) available for goralatide and Body Weight

ArticleYear
N-acetyl-seryl-aspartyl-lysyl-proline reduces cardiac collagen cross-linking and inflammation in angiotensin II-induced hypertensive rats.
    Clinical science (London, England : 1979), 2014, Jan-01, Volume: 126, Issue:1

    Topics: Amino Acid Oxidoreductases; Angiotensin II; Animals; Body Weight; Cardiomegaly; CD4-Positive T-Lymphocytes; Collagen; Extracellular Matrix; Hypertension; Inflammation; Lung; Male; NF-kappa B; Oligopeptides; Organ Size; Protein-Lysine 6-Oxidase; Rats; Rats, Inbred Lew; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Ventricular Function, Left; Ventricular Remodeling

2014
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.
    American journal of physiology. Heart and circulatory physiology, 2009, Volume: 296, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Blood Pressure; Body Weight; Cardiac Output; Cardiomegaly; Cardiotonic Agents; Collagen; Disease Models, Animal; Echocardiography, Doppler; Fibrosis; Galectin 3; Heart Rate; Hemodynamics; Inflammation; Infusions, Parenteral; Isoproterenol; Macrophages; Male; Mast Cells; Myocardial Contraction; Myocardium; Oligopeptides; Phosphorylation; Rats; Rats, Sprague-Dawley; Signal Transduction; Smad3 Protein; Stroke Volume; Time Factors; Transforming Growth Factor beta; Ventricular Function, Left; Ventricular Remodeling

2009
Ac-SDKP ameliorates the progression of lupus nephritis in MRL/lpr mice.
    International immunopharmacology, 2012, Volume: 14, Issue:4

    Topics: Actins; Animals; Antibodies, Antinuclear; Body Weight; Chemokine CCL2; Drug Administration Schedule; Female; Fibronectins; Gene Expression Regulation; Inflammation; Kidney; Leukocytes; Lupus Nephritis; Mice; Mice, Inbred MRL lpr; NF-kappa B; Oligopeptides; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha

2012
Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension.
    Hypertension (Dallas, Tex. : 1979), 2003, Volume: 42, Issue:6

    Topics: Angiotensins; Animals; Blood Pressure; Body Weight; Bradykinin; Collagen; Connective Tissue Growth Factor; Fibrosis; Heart Ventricles; Hypertension, Renovascular; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Male; Myocardium; Oligopeptides; Organ Size; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta

2003
Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation.
    Annals of the New York Academy of Sciences, 1991, Volume: 628

    Topics: Animals; Body Weight; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line; Cyclophosphamide; Cytarabine; Female; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Immunologic Deficiency Syndromes; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Oligopeptides; Transplantation, Heterologous

1991